Full Artificial Exosomes: Towards New Theranostic Biomaterials by García Manrique, Pablo et al.
Full Artificial Exosomes: Towards New Theranostic Biomaterials 1 
 2 
Pablo García-Manrique1,2, Gemma Gutiérrez1, M. Carmen Blanco-López2,* 3 
1Department of Chemical and Environmental Technology, University of Oviedo, Julián 4 
Clavería 8, 33006 Oviedo, Spain 5 
2Department of Physical and Analytical Chemistry, University of Oviedo, Julián Clavería 6 
8, 33006 Oviedo, Spain 7 
*Correspondence: cblanco@uniovi.es (M. Carmen Blanco-López) 8 
 9 
Abstract:  10 
Bio-nanotechnology routes have been recently developed to produce Full Artificial 11 
Exosomes: biomimetic particles aiming to overcome certain limitations regarding 12 
Extracellular Vesicles biology and manipulation. These particles could become true 13 
therapeutic biomaterials in the near future. Here, we outline the current preparation 14 
techniques, their explored and future possibilities and their present limits. 15 
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Extracellular Vesicles: The revolution of cell biology and physiology (365) 19 
The last decade represent a revolution in our knowledge about human body 20 
homeostasis based on cell communication.  Advances in our comprehension of the 21 
development and expansion of several pathologies are greatly due to the 22 
understanding of Extracellular Vesicles (EVs) biological behaviour, with special focus on 23 
Exosomes [1]. 24 
The increasing amounts of data about composition, biogenesis, and roles of exosomes 25 
in physiological and several pathologies  have opened new possibilities in diagnosis 26 
and therapy [2]. Exosomes have unique characteristics that emerge from their cellular 27 
origin. These confer them a high value as new biomarkers for diagnosis, stratification 28 
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and plannification/evaluation of treatment efficacy. They represent the access to a set 29 
of molecules with information about their origin cell and its status through all the 30 
lipids, proteins and nucleic acids travelling in both, the membrane and cargo. The 31 
opportunity to get all these valuable cellular info and the fact that it comes also from 32 
hard-to reach tissues, has promoted the term liquid-biopsy, a new frontier in the 33 
clinical field. 34 
On the other hand, exosomes combine the advantages of both nanocarriers, (particles 35 
for the efficient delivery of molecules), and therapy agents. Nowadays, they are 36 
considered as the most promising drug delivery systems, especially for gene therapy in 37 
different disorders (such as genetic deficiencies or anti-tumour progression) [3]. This 38 
attention is noticed in several papers published during the last 5 years, regarding the 39 
modification of targeting moieties and/or the encapsulation of endogenous and 40 
exogenous material during exosomes pre- or post-isolation from cell culturesThese 41 
represent the development of so-called Exosome-based Semi-Synthetic Nanovesicles, 42 
a subtype of artificial exosomes, which englobe all exosomes with modification for 43 
intended purposes. The have been even tested for autologous therapy. 44 
Besides the great explosion of techniques for semi-synthetic exosomes development, 45 
the main drawbacks concerning their clinical applications are the production, isolation, 46 
modification, and purification at large-scale clinical grade. This need is the driving force 47 
at the search for a new perspective: the design and manufacture of full synthetic 48 
exosomes mimetic particles based on Bio-nanotechnology. The following sections are 49 
an overview of these techniques, presented as the two trends in nanofabrication: the 50 
Top-Down and Bottom-Up approaches (see figure 1). 51 
Top-Down methodologies: Bioengineering Cells as membrane fragments precursors 52 
(378) 53 
Top-Down methodologies relies on the production of nanosized material by 54 
fragmentation of bigger and more complex units to smaller products. In this case, 55 
production of artificial exosomes starts from cultured cells. Different methodologies 56 
based on this approach have been developed, mainly for drug delivery, but also for cell 57 
proliferation enhancement and for the generation of exosome mimetic models applied 58 
to bio-distribution analysis (table 1). 59 
Extrusion over polycarbonate membrane filters is a common practice to reduce and 60 
homogenize size distribution of colloidal systems. Applying this technique to cultured 61 
cells, NVs for the treatment of tumours by targeted encapsulated chemotherapeutics 62 
have been developed with a simple commercial liposome extruder and diminishing 63 
pore size filters [4,5]. Moreover, a scaled-up version was developed with a device 64 
designed to be used with conventional lab centrifuges [6]. Mass production of NVs 65 
with this device was applied in a study for cell proliferation enhancement [7]. 66 
The use of microfluidics devices is also reported for artificial exosomes preparation. A 67 
simple pressurization over and array of parallel hydrophilic microchannels-based 68 
device was described for the production of NVs aimed to endogenous RNA delivery to 69 
targeted cell cultures [8]. The fabrication of microchannels on micro-blades (fabricated 70 
in silicon nitride) resulted on a device able to slice living cells during their flowing 71 
through the channels [9]. The incorporation of exogenous material to the cells 72 
suspension enhanced their encapsulation by plasma membrane fragments during re-73 
assembling, and described a method for in vitro exogenous material delivery.  74 
All these methods are suitable for the production of higher amounts of effective 75 
particles in comparison to natural exosome release yield (over 250 fold times larger). 76 
Sizing and biochemical profiling  of NVs had high similarities with exosomes. Their 77 
ability to exhibit receptors and co-receptors, essential to target and produce effective 78 
interactions with receptor cells populations, is of special relevance. And, of course, 79 
their natural origin from cells confers them immunotolerance. 80 
Beside these positive characteristics, these methods have some drawbacks. Cargo 81 
sorting lacks of selectivity due to passive encapsulation of surrounding medium during 82 
self-assembly of membrane fragments. Another relevant issue regarding the 83 
production of these mimetic particles is the need of final purifications steps identical 84 
to those used for exosome isolation, which requires trained personal and are time-85 
consuming. 86 
Bottom-Up techniques: mimicking plasma membrane through the preparation of 87 
artificial bilayers (410) 88 
Bottom-Up techniques, on the other hand, create complex structures of higher order 89 
by the manipulation of physical and chemical properties of some molecules 90 
(supramolecular chemistry). These methods are well known in the cosmetic and 91 
pharmaceutic industry by the preparation of liposomes, particles formed by a 92 
bilayered structure of lipids that resemble the plasma membrane. This connection is 93 
the starting point to design and create artificial exosomes: the preparation of a 94 
synthetic bilayer that is then functionalized with selected proteins to mimic desired 95 
exosomal functions. 96 
From the diverse methods for the preparation of liposomes, one of the more 97 
employed in the development of mimetic NVs is the Thin Film Hydration Method 98 
(TFHM). TFHM is a two-steps process where a dried film of lipids is hydrated by an 99 
aqueous media with the compounds to be encapsulated. Artificial exosomes have 100 
been produced with a classical liposome formulation [10] and a lipid composition 101 
simulating the exosomal one [11]. By chemistry-based bio-conjugation procedures, 102 
MHC Class I/peptide complexes and ligand involved in T-Cell receptor interactions and 103 
activation have been attached to vesicles for immunotherapy (ex vivo and in vivo cell 104 
expansion). Also the incorporation of APO2L/TRIAL for induction of apoptosis and 105 
down-regulation of T-Cell activation in autoimmune diseases, such as antigen-induced 106 
arthritis, was reported [11]. These NVs were evaluated in the treatment of 107 
hematologic tumour cells [12]. 108 
More recently, a different method based on micro-emulsification and micelle 109 
assembling was described for the encapsulation of BSA as a model to simulate artificial 110 
antigen-presentation to Dendritic Cells [13]. To specifically target DCs, a monoclonal 111 
antibody against DEC205 (a highly expressed receptor on the surface of DCs that 112 
facilitate endocytosis) was selected.  113 
The main advantage of this strategy relies on the production of a high pharmaceutical 114 
grade product, since the final composition is fixed by the selected formulation. 115 
However, publications on this topic are still scarce. Besides, since these are methods 116 
adapted from the conventional routes of liposome production of liposomes, expensive 117 
high purity lipids are required (especially if functionalization with proteins is going to 118 
be carried out). The attachment of multiple molecules to the NVs is also challenging, 119 
since conjugation procedures requires stable and specific conditions [12].  120 
On the other hand, encapsulation of nucleic acids is a challenge process that deals with 121 
a very unstable type of molecules, and seems that the best encapsulation efficiencies 122 
are obtained with cationic lipids, more immunogenic than regular counterparts [13].    123 
Concluding remarks and future perspectives (259) 124 
The incipient recent success in basic and clinical studies by using full artificial exosomes 125 
has created the basis of the future nanomedicine. The multidisciplinary approach with 126 
contributions from molecular biology, engineering, biotechnology and chemistry will 127 
be essential to overcome the limits present in up-today methods. Further research 128 
work is necessary to improve the methods of production, but the solution seems to 129 
pass through the combination of techniques designed with both approaches: semi- 130 
and  full synthetic artificial exosomes.  131 
Techniques for the modification of cells prior to exosome isolation, could be perfectly 132 
coupled to any Top-Down method in order to tailor artificial exosomes with 133 
complementary elements to those natural presented in selected donor cells. Possibly, 134 
these could also be used to enhance the physical stability of generated products, a not 135 
fully studied property. 136 
Regarding Bottom-Up techniques, microfluidics, a really versatile platform for particle 137 
production and drugs encapsulation, represent a very promising approach. This 138 
enables rapid testing of multiples formulation thanks to the quickness in product 139 
generation, but also with the consuming of  significantly less amount of chemicals. In 140 
that direction, alternatives to lipids may be explored. Currently, our research group is 141 
testing the possibilities of niosomes (vesicles formulated with Non-ionic surfactants) as 142 
an alternative to lipid-based particles in the development of artificial exosomes. The 143 
main advantages of these vesicles are their wide spectra of starting compounds, more 144 
economical, better physical and chemical stability, and high grade of biocompatibility .  145 
As new productions routes are improved, novel nanovesicles closer to real exosomes 146 
will be available, making possible personal nanomedicine and theranostics agents 147 
adapted to particular needs. 148 
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Table 1. Full artificial exosomes published works based on Top-Down and Bottom-Up Bio-nanotecnology. 177 
Works based on Top-Down approach 
Mechanism of membrane 
fragmentation 
Precursor Cell lines Type and examples of material incorporated Application Reference 
Manual extrusion over 
polycarbonate membrane filters 
with a device for liposome 
preparation 
Human Monocytes (U937) and 
Murine mouse Macrophages (Raw 
264.7) 
Exogenous, chemotherapeutic drugs (Doxorubicin, 
5-FU, gemcitabine and carboplatin) 
Targeted delivery of chemotherapeutics to an in vitro model 
(TNFα- treated HUVEC) and in vivo induced malignant 
tumours (CT26 mouse colon adenocarcinoma cells)  
[4] 
Murine mouse Macrophages (Raw 
264.7) 
Exogenous, Radiolabelling agent 99mTc-HMPAO In vivo bio-distribution of exosomes and artificial 
counterparts 
[5] 
Centrifugal-induced extrusion over 
membrane filters in a device 
designed to be used in lab 
centrifuges 
Murine mousse embryonic stem cell 
line-D3 
Endogenous, Precursor cells characteristic RNA 
(mOct 3/4 and mNanog) 
Gene delivery to NIH-3T3 fibroblast cells [6] 
Murine mousse embryonic stem cell 
line-D3 
No intention to encapsulate any specific 
compounds 
Enhance in vitro cell proliferation for regenerative medicine 
(Mice skin fibroblasts) 
[7] 
Pressurization over hydrophilic 
microchannels array on a 
microfluidic device 
Murine mousse embryonic stem cell 
line-D3 
Endogenous, Precursor cells characteristic RNA 
(mOct 3/4 and mNanog) 
Gene delivery to NIH-3T3 fibroblast cells [8] 
Living cells slicing with silicon 
nitride blades in a microfluidic 
device 
Murine mousse embryonic stem cell 
line-D3 
Exogenous, Polystyrene beads as representative 
exogenous material 
Material delivery to Mousse embryonic fibroblasts [9] 
Works based on Bottom-Up approach 
Type of formulation NVs preparation strategy Proteins for NVs functionalization Application Reference 
Classical liposome, PC:Chol Thin Film Hydration Method (TFHM) 
and maleimide based bio-conjugation 
strategy 
MHC Class I peptide complexes and FAB regions 
against T-Cell receptors for adhesion, early and 
late activation, and survival. 
Ex vivo and In vivo T-Cell expansion for immunotherapies  [10] 
Mimicking exosomes lipid 
composition, PC:Chol:SM 
TFHM and Ni2+/His-Tag protein 
coordination as bio-conjugation 
strategy 
APO2L/TRIAL-His10 recombinant proteins Down-regulation of T-Cell activation in an autoimmune 
disease animal model (antigen-induced arthritis) 
 





Micro-emulsion and micelle 
assembling method for vesicle 
formation 
Monoclonal antibody against DEC205 Dendritic 
Cell antigen 
Probe of concept of artificial antigen presentation to 
Dendritic Cells 
[13] 
99mTc-HMPAO: 99mTc-Hexamethylpropyleneamineoxime; Chol: Cholesterol; CpEL: Chemopor EL; DOPE: Dioleoyl-Phosphoethanolamine; HUVEC: Human Umbilical Vein Endothelial Cells;  MHC: 178 
Major Histocompatibility Complex; NVs: Artificial exosomes, here referred as the general term Nanovesicles; PC: Phosphatidylcholine; SM: Sphingomyelin; TFHM: Thin Film Hydration Method;  179 
  180 
Figure captions: 181 
Fig.1. Advantages (green) and disadvantages (red) of the two approaches for bio-nanotechnological development of full artificial exosomes as 182 
theranostic agents.  183 
 184 
Top-Down methods Bottom-Up methods
Full Artificial Exosome
-Mass production of NVs
-NVs with natural target properties, specificity
tuneable by precursor cell line selection
-Expression of receptor and co-receptor
allowing true cell interactions
-Naturally immunotolerated
-No selectivity during cargo sorting
-Need of purification steps, with trained
personal and time consumption
-Production of a high pharmaceutical 
grade product
-Ideal platform for basic studies of 
independent elements
-Functionalization not scaled-up
-Challenging incorporation of multiple 
surface elements
A key to the future 
nanomedice?
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